Clik here to view.
Brean Capital Slashes Price Target on Keryx Biopharmaceuticals (KERX) on Back...
In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while slashing the price target to $10 (from...
View ArticleClik here to view.
Brean Capital Reiterates Buy on Heron Therapeutics Inc (HRTX) Following...
In a research report issued Thuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a price target of $55, after the drug maker...
View ArticleClik here to view.
Brean Capital Reiterated Buy on Neuralstem, Inc. (CUR) Following Preclinical...
In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), with an $8.00 price target, after the biotech company...
View ArticleClik here to view.
Brean Capital Analyst Downgrades Keryx Biopharmaceuticals (KERX) Following...
Keryx Biopharmaceuticals (NASDAQ:KERX) shares are tumbling nearly 12% in early trading, following an impending supply interruption for key pipeline drug, Auryxia, a drug created to treat patients on...
View ArticleClik here to view.
Brean Capital Cuts Price Target for Merrimack Pharmaceuticals Inc (MACK) on...
In a research report issued Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), and reduced the price target to $13 (from...
View ArticleClik here to view.
Brean Capital Analyst Bullish on Inovio Pharmacueticals Inc (INO) Amid 2Q:16...
In a research note issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) with a price target of $18, after the small...
View ArticleClik here to view.
Brean Capital Weighs In On Heron Therapeutics Inc (HRTX) Following FDA...
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a price target of $55, after the company...
View ArticleClik here to view.
Brean Capital Slashes Price Target for Neuralstem, Inc. (CUR) to Reflect More...
In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), while slashing the price target to $4.00 (from $8.00),...
View ArticleClik here to view.
Brean Capital Downgrades Medivation Inc (MDVN) in Wake of Pfizer Merger...
Yesterday morning, Medivation Inc (NASDAQ:MDVN) announced that it entered a definitive merger agreement with Pfizer Inc. (NYSE:PFE), totaling about $14 billion in enterprise value. Under this deal,...
View ArticleClik here to view.
Brean Capital Chimes in on Neuralstem, Inc. (CUR) Following Agreement with...
Neuralstem, Inc. (NASDAQ:CUR) shares are climbing nearly 6% after announcing this morning it had entered into an official agreement with Tianjin Pharmaceutical Holding Group, where the firm will garner...
View ArticleClik here to view.
Repros Therapeutics: PRAC Conclusion On TRT Helps Case For Androxal, Says...
In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on ... The post Repros Therapeutics: PRAC Conclusion On TRT Helps Case For Androxal, Says Brean...
View ArticleClik here to view.
Brean Capital Maintains Buy On Chimerix Following Preliminary Data Release At...
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Chimerix ... The post Brean Capital Maintains Buy On Chimerix Following Preliminary Data Release...
View ArticleClik here to view.
Brean Capital Maintains Buy On OHR Pharmaceutical Following End Of Phase 2...
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating ... The post Brean Capital Maintains Buy On OHR Pharmaceutical Following End Of Phase 2...
View ArticleClik here to view.
Brean Capital Maintains Buy On Chimerix Following Analyst Day
In a research report issued today, Brean Capital analyst Jonathan Aschoff assigned a Buy rating ... The post Brean Capital Maintains Buy On Chimerix Following Analyst Day appeared first on Smarter...
View ArticleClik here to view.
Brean Capital Reiterates Buy On Intellipharmaceutics Following FY3Q14 Results
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating ... The post Brean Capital Reiterates Buy On Intellipharmaceutics Following FY3Q14 Results appeared...
View ArticleClik here to view.
Brean Capital Maintains Buy On Repros, $41 PT
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating ... The post Brean Capital Maintains Buy On Repros, $41 PT appeared first on Smarter Analyst.
View ArticleClik here to view.
Brean Capital Maintains Buy On Progenics Following Phase 2 Data Of PSMA...
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating ... The post Brean Capital Maintains Buy On Progenics Following Phase 2 Data Of PSMA...
View ArticleClik here to view.
Brean Capital Reiterates Buy On Repros Therapeutics Following Long-Term Phase...
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reiterated a Buy ... The post Brean Capital Reiterates Buy On Repros Therapeutics Following Long-Term Phase 3 Data...
View ArticleClik here to view.
Brean Capital Maintains Hold On Biomarin Following In-Line 3Q14
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Hold rating on ... The post Brean Capital Maintains Hold On Biomarin Following In-Line 3Q14 appeared first on...
View ArticleClik here to view.
Brean Capital Maintains Buy On Repros Therapeutics Following Management Meetings
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating ... The post Brean Capital Maintains Buy On Repros Therapeutics Following Management Meetings appeared...
View Article
